DMRA Damora Therapeutics Inc.

Price (delayed)

$22.47

Market cap

$1.38B

P/E Ratio

4.26

Dividend/share

N/A

EPS

$5.28

Enterprise value

$850.2M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 76
Relative Profitability: Rel. Profitability: 0

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase ...

Highlights
The quick ratio has soared by 191% YoY and by 74% from the previous quarter
DMRA's EPS has surged by 134% year-on-year and by 33% since the previous quarter
DMRA's net income is down by 12% since the previous quarter

Key stats

What are the main financial stats of DMRA

DMRA stock price

How has the Damora Therapeutics stock price performed over time
Intraday
0.63%
1 week
-9.54%
1 month
-13.34%
1 year
580.91%
YTD
-2.35%
QTD
-13.24%

Financial performance

How have Damora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$239.08M
Net income
-$235.09M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 13% QoQ
DMRA's net income is down by 12% since the previous quarter

Price vs fundamentals

How does DMRA's price correlate with its fundamentals

Growth

What is Damora Therapeutics's growth rate over time

Valuation

What is Damora Therapeutics stock price valuation
P/E
4.26
P/B
2.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DMRA's EPS has surged by 134% year-on-year and by 33% since the previous quarter
DMRA's price to book (P/B) is 139% more than its last 4 quarters average of 1.1
DMRA's equity has surged by 113% since the previous quarter

Efficiency

How efficient is Damora Therapeutics business performance
Damora Therapeutics's ROE has soared by 60% from the previous quarter but it has decreased by 22% YoY
The return on assets has surged by 59% since the previous quarter but it has declined by 29% year-on-year

Dividends

What is DMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMRA.

Financial health

How did Damora Therapeutics financials performed over time
The quick ratio has soared by 191% YoY and by 74% from the previous quarter
The current ratio has soared by 134% YoY and by 73% QoQ
Damora Therapeutics's debt is 100% less than its equity
DMRA's equity has surged by 113% since the previous quarter
Damora Therapeutics's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.